Aktuellt
SENASTE
Redeye maintains its fair value range for Sleep Cycle following the Q4 2024 report, which met our sales expectations, while EBIT exceeded our forecasts. Based on the strong performance in 2024, we believe Sleep Cycle is well-positioned to continue delivering attractive returns to shareholders and grow its business simultaneously. The proposed raised dividend for 2025 and the updated margin targets reflect solid execution from the new management team
LÄS MER
